An observational study in Diffusion Magnetic Resonance Imaging and Brain White Matter Diseases, sponsored by The General Authority for Teaching Hospitals and Institutes. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by The General Authority for Teaching Hospitals and Institutes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Brain white matter diseases (WMDs) are a group of neurological conditions that involve changes to the brain's white matter, often leading to cognitive, motor, and sensory impairments.
Diffusion Magnetic Resonance Imaging (dMRI), has emerged as a powerful non-invasive imaging tool for evaluating microstructural changes in brain white matter. This protocol aims to investigate the role of dMRI in the early identification and characterization of brain white matter diseases, focusing on its potential for detecting abnormalities before the onset of overt clinical symptoms.
Diffusion-weighted imaging (DWI), one of the first advanced magnetic resonance imaging (MRI) techniques, has rapidly ascended on the basis of its applicability in strokes and some infectious diseases. Restricted diffusion is significant information in the context of vascular ischemia, helping to delimit the brain-damaged area
39 studies on the registry are indexed under Leukoencephalopathies; 16 are open to participants now.
This study's planned enrollment of 150 is above the median of 100 across 28 observational studies indexed under Leukoencephalopathies.
Browse Leukoencephalopathies studies →The General Authority for Teaching Hospitals and Institutes is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will be a multicenter, cross-sectional study will be conducted on patients diagnosed with suspected early-stage white matter disease (e.g., multiple sclerosis, small vessel disease, Alzheimer's disease, frontotemporal dementia, leukoaraiosis) will be enrolled. Healthy age-matched controls will also be included for comparison.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with suspected early-stage white matter disease (e.g., multiple sclerosis, small vessel disease, Alzheimer's disease, frontotemporal dementia, leukoaraiosis) will be enrolled.
Other: Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
Sensitivity of diffusion magnetic resonance imaging
Sensitivity of diffusion magnetic resonance imaging to predict the early evaluation of brain white matter diseases
Time frame: Immediately after diffusion magnetic resonance imaging (Up to 1 hour)
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The General Authority for Teaching Hospitals and Institutes